Abstracts Archive - Page 944 of 2607 - ACR Meeting Abstracts

Abstract Number: 1614 • ACR Convergence 2020
Use of a Best Practice Alert to Encourage Transition Planning and Readiness
Bernard Danna¹, Monique Maher¹, Marietta DeGuzman², Andrea Ramirez¹, Eyal Muscal², Amanda Brown², Martha Curry², Maria Pereira², M. Brad Nelson², Pooja Patel², Ugo Awa², LeeGee Huang³, Blanca Sanchez-Fournier³, JaLeen Rogers³, Ariel Coleman³, Anne Dykes³, Miriah Gillispie-Taylor² and Tiphanie Vogel⁴, ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine, Houston, ³Texas Children's Hospital, Houston, ⁴Baylor College of Medicine/Texas Children's Hospital, Houston, TX
Background/Purpose: Transitioning children with chronic diseases from pediatric to adult care can be challenging. Patients are faced with the emotional shock of entering a new…
Abstract Number: 1615 • ACR Convergence 2020
Assessing Preparation for Care Transition Among Adolescents with Rheumatologic Disease: A Quality Assessment with Patient Survey
Jordan Roberts¹, Olha Halyabar², Carter Petty³ and Mary Beth Son¹, ¹Boston Children's Hospital, Boston, MA, ²Children's Hospital/Boston Medical Center, Boston, MA, ³Boston Childrens Hospital, Institutional Centers for Clinical and Translational Research, Boston, MA
Background/Purpose: Despite the risk for poor outcomes and gaps in care in the transition from pediatric to adult care, most pediatric rheumatology centers lack formal…
Abstract Number: 1616 • ACR Convergence 2020
Systematic Review of Effectiveness Outcomes Reported in Rheumatology Transition Literature
Heather Bannerman¹, Karen Beattie¹, Avanti Patel², Milica Tanic², Michelle Batthish³ and Mark Matsos², ¹McMaster University, Hamilton, ON, Canada, ²McMaster University, Hamilton, Canada, ³McMaster Children's Hospital, Hamilton, ON, Canada
Background/Purpose: In young patients with rheumatologic disease, transition from pediatric to adult care is a complex process. Poor transitional care leads to health deterioration, loss…
Abstract Number: 1617 • ACR Convergence 2020
New Juvenile Idiopathic Arthritis Quality Measure Set for the Pediatric Rheumatology Care and Outcomes Improvement Network
Julia Harris¹, Esi Morgan², Sheetal Vora³, Mileka Gilbert⁴, Cagri Yildirim-Toruner⁵, Nancy Griffin⁶, Kerry Ferraro⁷, Stephanie Loos⁶, Tingting Qiu⁸, Anne Paul⁹, Jon Burnham¹⁰, Michelle Batthish¹¹, Beth Gottlieb¹², Danielle Bullock¹³, Melissa Hazen¹⁴, Ronald Laxer¹⁵, Tzielan Lee¹⁶, Melissa Mannion¹⁷, Judyann Olson¹⁸, Nancy Pan¹⁹, Michael Shishov²⁰, Charles Spencer²¹, Jennifer E Weiss²² and C. April Bingham²³, ¹Children's Mercy Kansas City, Overland Park, KS, ²Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ³Atrium Health Levine Children's Hospital, Charlotte, NC, ⁴Medical University of South Carolina, Charleston, SC, ⁵Nationwide Children's Hospital, Houston, TX, ⁶Cincinnati Children's Hospital Medical Center, Cincinnati, ⁷Pediatric Rheumatology Care and Outcomes Improvement Network, Cincinnati, ⁸Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁹Cincinnati Children’s Hospital Medical Center, University of Cincinnati, Cincinnati, ¹⁰Children's Hospital of Philadelphia, Philadelphia, PA, ¹¹McMaster Children's Hospital, Hamilton, ON, Canada, ¹²Cohen Children's Medical Center, Lake Success, NY, ¹³University of Minnesota, Minneapolis, MN, ¹⁴Boston Children's Hospital, Boston, MA, ¹⁵The Hospital for Sick Children, Toronto, ON, Canada, ¹⁶Stanford University School of Medicine, Palo Alto, CA, ¹⁷University of Alabama at Birmingham, Birmingham, AL, ¹⁸Medical College of Wisconsin, Milwaukee, WI, ¹⁹Hospital for Special Surgery, New York, NY, ²⁰Phoenix Children's Hospital, Phoenix, AZ, ²¹University of Mississippi, Jackson, MS, ²²PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²³Penn State Children's Hospital, Allentown, PA
Background/Purpose: The Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) is a learning network to support pediatric rheumatology centers in improving care delivery and patient…
Abstract Number: 1618 • ACR Convergence 2020
Frequency and Cost of Repeat HLA-B27 Testing Within the National Capital Consortium over a Calendar Year
Anna Stein¹, Caleb Anderson² and Angelique Collamer³, ¹Walter Reed National Military Medical Center, Takoma Park, MD, ²Walter Reed National Military Medical Center, Bethesda, MD, ³Walter Reed National Military Medical Center, Silver Spring, MD
Background/Purpose: Human leukocyte antigens (HLAs) are proteins encoded for by the major histocompatibility complex located on the short arm of chromosome six. One such allele,…
Abstract Number: 1619 • ACR Convergence 2020
Immunoglobulin G Subclass Ordering Patterns for IgG4-Related Disease at an Academic Medical Center
Lena Eder¹ and David Leverenz², ¹Duke University Hospital, Chapel Hill, NC, ²Duke University, DURHAM, NC
Background/Purpose: We have noticed an increasing number of serum IgG4 levels ordered over the last several years at our institution. This study was performed to…
Abstract Number: 1620 • ACR Convergence 2020
Hepatitis B Screening Practices When Prescribing Tocilizumab or Tofacitinib in Real World Practice
Naomi Serling-Boyd¹, Amir Mohareb², Arthur Kim², Emily Hyle² and Zachary Wallace³, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, ³Massachusetts General Hospital, Newton, MA
Background/Purpose: Hepatitis B virus (HBV) reactivation can complicate treatment with immunosuppressive medications. Reactivation risk varies by the status of HBV infection but has been reported…
Abstract Number: 1621 • ACR Convergence 2020
Cervical Cancer Screening Among Women with Systemic Lupus Erythematosus or Prescribed Tumor Necrosis Alpha-inhibitors Who Receive Outpatient Rheumatology Care
Mehret Birru Talabi¹, Kwonho Jeong¹, Kaleab Abebe¹, Megan Clowse², Robyn Domsic³ and Sonya Borrero¹, ¹University of Pittsburgh, Pittsburgh, PA, ²Duke University, Chapel Hill, NC, ³University of Pittsburgh School of Medicine, Pittsburgh, PA
Background/Purpose: Cervical cancer screening is important for women with systemic lupus erythematosus (SLE) and women prescribed TNF-alpha inhibitors (TNFi), as they have an increased risk…
Abstract Number: 1622 • ACR Convergence 2020
Determining the Zoster Vaccination Rate Among Veterans on Chronic Immunosuppressive Therapy at the Southeast Louisiana Veterans Healthcare System – a Quality Indicator
Hannah Kenninger¹, Rachel Dayno¹, Nkechinyere Emejuaiwe², Ileannette Robledo-Vega³, Whitney Bembry¹, Myriam Guevara⁴ and Soham Mahato⁵, ¹Tulane University School of Medicine, New Orleans, LA, ²Southeast Louisiana Veterans Healthcare System, New Orlenas, LA, ³Louisiana State University Health Sciences Center, New Orlenas, LA, ⁴Lousiana State University Health Sciences Center, New Orleans, LA, ⁵LSUHSC School of Public Health, New Orleans, LA
Background/Purpose: Herpes Zoster (HZ) causes an infection commonly known as shingles. Patients with HZ are at increased risk for post-herpetic neuralgia, which is painful for…
Abstract Number: 1623 • ACR Convergence 2020
Improving Pneumococcal Vaccination Rates Among Immunosuppressed Adults in an Academic Rheumatology Clinic Utilizing a Nurse Driven Protocol
Elena Joerns¹, Bonnie Bermas², Puneet Bajaj³, Nagendra Pokala¹, Reuben Arasaratnam⁴, Joan Reisch¹ and Dan (Clarie) Wang¹, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²UTSouthwestern.edu, Dallas, TX, ³UT Southwestern, Dallas, TX, ⁴UT Southwestern Medical Center, Dallas, TX
Background/Purpose: Rheumatology patients are particularly vulnerable to pneumococcal infection due to both their underlying disease and immunosuppressive therapy. Thus, quality improvement metrics include increasing pneumococcal…
Abstract Number: 1624 • ACR Convergence 2020
Improving Pneumococcal Vaccination in Veterans with Rheumatic Diseases
Sarah Homann¹, Michelle Ormseth², Christianne Roumie² and Robert Dittus², ¹Veterans Affairs Tennessee Valley Healthcare System / Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Patients with rheumatic diseases are at increased risk of invasive pneumococcal disease. Both pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23) are recommended…
Abstract Number: 1625 • ACR Convergence 2020
Pneumocystis Jiroveci Pneumonia in Immunocompromised Patients with Rheumatologic Disease in a Single, Tertiary Medical Center
Zahra Rehman¹, Megan Krause¹, Jessica Newman² and Pooja Bhadbhade¹, ¹The University of Kansas Medical Center, Kansas City, KS, ²The University of Kansas Medical Center, Kansas City
Background/Purpose: Pneumocystis jiroveci pneumonia (PJP) is rare, but can be fatal among immunocompromised. There is no consensus on indications for PJP prophylaxis in rheumatologic patients.…
Abstract Number: 1626 • ACR Convergence 2020
Long-Term Follow-Up of Renal Transplantation Due to Lupus Nephritis. Single Universitary Center Experience
Lara Sanchez-Bilbao¹, Marina De Cos-Gomez², Inigo Gonzalez-Mazon³, David Martinez-Lopez⁴, Juan Carlos Ruiz-San Millan², Miguel Ángel González-Gay⁵ and Ricardo Blanco¹, ¹Hospital Universitario Marques de Valdecilla, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, ³Hospital Universitario Marques de Valdecilla, Bezana, Spain, ⁴Hospital Universitario Marques de Valdecilla, Santander (SPAIN), Spain, ⁵Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain
Background/Purpose: Lupus nephritis (LN) is a severe complication of systemic lupus erythematosus (SLE). Approximately 10-20% of LN develop end stage renal disease (ESRD) and need…
Abstract Number: 1627 • ACR Convergence 2020
Phase I Trial of High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients with Mild COVID-19: A Study in the Effects of Shifting Public Opinion on Patient Enrollment
Patrick Onkka¹, Pankti Reid¹, Iazsmin Bauer Ventura¹, Brian Labadie² and Reem Jan¹, ¹University of Chicago, Chicago, IL, ²University of Chicago, Chicago
Background/Purpose: Coronavirus disease 2019 (COVID-19) was first recognized in December 2019 and quickly became a global pandemic within months. Amidst a myriad of uncertainties, early…
Abstract Number: 1628 • ACR Convergence 2020
Management of Gout After Pegloticase; Observations of US Clinical Practice from Trio Health and the American Rheumatology Network (ARN)
Nehad Soloman¹, Mona Amin², Simon Helfgott³, Alexander Hu⁴, Kent Kwas Huston⁵, Jordan Leonard⁶, Kelsey Milligan⁷, Scott Milligan⁷, Jasvinder Singh⁸, John Tesser⁹ and Colin Edgerton¹⁰, ¹Arizona Arthritis & Rheumatology Associates, P.C., Peoria, AZ, ²Arizona Arthritis & Rheumatology Associates, P.C., Scottsdale, AZ, ³BWH- HMS, Boston, MA, ⁴Arizona Arthritis & Rheumatology Associates, P.C., New Orleans, LA, ⁵Kansas City Physician Partners, Kansas City, MO, ⁶Arizona Arthritis & Rheumatology Associates, P.C., Phoenix, AZ, ⁷Trio Health, Louisville, CO, ⁸University of Alabama at Birmingham, Birmingham, AL, ⁹Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ¹⁰Articularis Healthcare, Summerville, SC
Background/Purpose: Pegloticase is approved for severe gout in patients that are intolerant to, or whose disease is ineffectively controlled by, other uric acid lowering therapies…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].